Review
doi: 10.1016/s0167-4781(98)00134-1.
Clinical applications of anticancer drugs targeted to topoisomerase II
Affiliations
- PMID: 9748560
- DOI: 10.1016/s0167-4781(98)00134-1
Item in Clipboard
Review
Clinical applications of anticancer drugs targeted to topoisomerase II
Biochim Biophys Acta.
.
Abstract
Agents which 'poison' the enzyme topoisomerase II, have proven to be useful drugs for cancer treatment. Six antineoplastic drugs, which target topoisomerase II (doxorubicin, daunorubicin, idarubicin, mitoxantrone, etoposide and teniposide) are currently approved for clinical use in the United States. In this paper, the strategies and goals of cancer chemotherapy are summarized for the non-clinician. The use, pharmacology and toxicity of each of the six currently approved topoisomerase II inhibiting agents are reviewed.
Similar articles
-
Toxicity of the topoisomerase II inhibitors.Expert Opin Drug Saf. 2005 Mar;4(2):219-34. doi: 10.1517/14740338.4.2.219. Expert Opin Drug Saf. 2005. PMID: 15794715 Review.
-
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.Drug Saf. 2006;29(3):209-30. doi: 10.2165/00002018-200629030-00005. Drug Saf. 2006. PMID: 16524321 Review.
-
Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.BMC Cancer. 2006 Apr 21;6:101. doi: 10.1186/1471-2407-6-101. BMC Cancer. 2006. PMID: 16630341 Free PMC article.
-
Etoposide: four decades of development of a topoisomerase II inhibitor.Eur J Cancer. 1998 Sep;34(10):1514-21. doi: 10.1016/s0959-8049(98)00228-7. Eur J Cancer. 1998. PMID: 9893622 Review.
-
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.Drugs. 1995 Jan;49(1):11-9. doi: 10.2165/00003495-199549010-00002. Drugs. 1995. PMID: 7705211 Review.
Cited by
-
Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants.G3 (Bethesda). 2015 Jul 21;5(9):1925-35. doi: 10.1534/g3.115.020560. G3 (Bethesda). 2015. PMID: 26199284 Free PMC article.
-
Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.J Interdiscip Nanomed. 2018 Oct 15;3(3):146-159. doi: 10.1002/jin2.51. eCollection 2018 Sep. J Interdiscip Nanomed. 2018. PMID: 30443411 Free PMC article.
-
Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.Mol Cell Biol. 2000 Dec;20(24):9127-37. doi: 10.1128/MCB.20.24.9127-9137.2000. Mol Cell Biol. 2000. PMID: 11094065 Free PMC article.
-
Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.BMC Chem Biol. 2009 Jan 7;9:1. doi: 10.1186/1472-6769-9-1. BMC Chem Biol. 2009. PMID: 19128485 Free PMC article.
-
Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad.Biochim Biophys Acta. 2007 Aug;1770(8):1194-203. doi: 10.1016/j.bbagen.2007.04.008. Epub 2007 May 3. Biochim Biophys Acta. 2007. PMID: 17544220 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
